The Now Corporation (NWPN)
Alert Price: $0.0073
Float: 90.697M
Technical Analysis
Company Website | Recent News
We are once again swinging for the fences with a proven winner that appears to be on the verge of another breakout!
Please turn your immediate attention to The Now Corporation (NWPN).
The last time we brought this low-float alert to you attention shares ran up over +110% in just one session!
Once again, NWPN’s chart is showing off several breakout signals, and it deserves to be on the top of your watchlist.
With CBD Prohibition Looking on its Last Legs, NWPN May be the Hottest Under the Radar CBD Stock Set to Skyrocket!
In the midst of growing worldwide interest in medicinal cannabis, The Now Company (NWPN) is lighting up on Wall Street with enormous profit potential ahead!
Cannabis is expected to heavily disrupt the pharmaceutical industry as patients all over the world continue to report on the medicinal benefits of the all-natural plant.
This may be the perfect time to start paying heavy attention to the sector and to NWPN, a bio-pharmaceutical research company that is focused on improving the health and wellness of patients worldwide and is building a dynamic, innovative and forward-looking research, development, education, and testing company serving the fast growing cannabis industry across the US and Canada.
About the Now Corporation
The Now Corporation is a bio-pharmaceutical research company focused on the research, education and production of Scientific-Grade Cannabidiol (CBD) from hemp and Tetrahydrocannabinol (THC) to be used for medicinal purpose, while focusing on pursuing business opportunities in the growing medical and recreational marijuana sector.
Through its acquired assets, the company is seeking to invest in its businesses associated with the growing, marketing, research and development, training, distribution and retail sale of scientific-grade medicinal cannabis, both in the United States and Canada.
This includes, but is not limited to, food, paper, and textiles derived from Hemp.
The company additionally provides Credible Scientific Research Data to the heavily regulated medical and recreational marijuana industries - currently one of the fastest growing industries in North America.
NWPN is unlocking and advancing medicine for human life around the world, at every stage of life!
The Short Term Goal
The company has created agreements with top research scientists from major Universities and have utilized their existing labs to perform expensive research using cannabinoid compounds which are in cannabis plants.
From the research, the company will be able to publish research white papers that will contain credible data from these research laboratories.
As a result, the information that NWPN publishes will start to establish increased credibility in the industry, and will allow the company's products to be prescribed by physicians since they will be able to access the information in their databases.
These studies will answer many questions and stop false data and rumors about CBD/THC derived from cannabis, and the effects on the human body.
The Long Term Goal
The company desires to have an FDA approved medicine that focuses on nausea and other ailments. Due to the FDA approval, it will be available for pharmacies to dispense, and will be on the approved list for insurance companies to pay for.
Ultimately, the company will pursue patenting the compound on a molecular level, similar to Pfizers patent on the drug, Vi-agra.
Nausea and vomiting are not diseases, but they are symptoms of many conditions such as: Motion sickness or seasickness. Early stages of pregnancy (nausea occurs in approximately 50%-90% of all pregnancies; vomiting in 25%-55%).
This makes the market for an anti-nausea medicine significant.
What Makes the Company Stand Out
NWPN will have a scientifically tested product. The existing products that are available on the markets may not be safe.
For example, what is the safe dosing for CBDs in the human body? What is the effectiveness rate when humans consume CBD, and how much can a human take before it becomes toxic to the body?
The Federal government, along with State governments must find out this answer before deeming it safe. The company's research does not start at the plant, they will also research air, soil, and water, from a seed genetic level up to a mature plant.
One reason to closely follow NWPN is because of big pharma...
On November 19, 2019, The FDA warned 15 companies for illegally selling various
products containing cannabidiol as the agency details safety concerns.
Violations included marketing unapproved new human and animal drugs, selling CBD products as dietary supplements, and adding CBD to human and animal foods.
These are concerning issues that take place in the marijuana industry and through the company's research, NWPN will address such safety concerns by performing rigorous testing of CBD compounds.
By publishing a scientific white paper based on the study, it will additionally allow the FDA to review the information and have credible data to make concrete rulings.
While the industry is big, safety concerns are still prevalent creating a demand for the type of research NWPN is involved with.
Big pharma is definitely recognizing the very lucrative opportunity when it comes to medicinal marijuana.
Cannabis is inexpensive to produce, and with the right policies, there could be widespread access to those in need, which disrupts the traditional marketplace.
A recent report found that Big Pharma stands to lose as much as $4 billion per year if medical marijuana became legal in all 50 states. The information is based off a study from 2016 by the University of Georgia, which found that states with legalized medicinal cannabis had less Medicare prescriptions than those where it's still illegal.
The study found that already pharmaceutical companies are losing $166 million annually on drugs where marijuana is now offered as an alternative.
Big pharma will have no choice but to jump onto the cannabis bandwagon if they want to continue capitalizing on patients!
Pharmaceutical giants are already preparing for the cannabis revolution and are building connections. Plus with the rise in opioid lawsuits, it may lead to many drug companies looking to cannabinoids in the search for less-addictive pain relievers.
This will only further fuel the momentum of the cannabis revolution and these pharma giants could be going on shopping sprees to scoop up smaller players.
When investors look back on the cannabis industry a decade from now, they're liable to find one of the fastest growth trends on the planet and NWPN could emerge as one of the biggest winners and acquisition targets!
A Big Vote Is On Its Way
Members of the US House of Representatives are expected to vote later this month on The Marijuana Opportunity, Reinvestment, and Expungement Act... otherwise known as The MORE Act.
This is HUGE as it is the very first time that the U.S. House will vote on federal marijuana legalization!
"It's about time," Rep. Jerry Nadler told USA TODAY, calling it a "historic vote" marking the beginning of the end of the federal government's "40-year, very misguided crusade" against marijuana.
Pot stocks like NWPN could be gearing up for a big rally as the U.S. finally pushes forward with federal marijuana legislation!
The Top 5 Reasons to Have The Now Company (OTC: NWPN) on Your Radar Right Now:
The company's CEO Ken Williams has spent five years leading public companies in the Legal Marijuana Industry, three decades of Advanced Technology Engineering, and as an executive for multi-million-dollar brands!
The U.S. is getting closer to federalizing marijuana on a federal level. The Federal government can't stick its head in the sand much longer and ignore the immense profit opportunity of the industry and the demands of the people. This could create an enormous rally for pot related stocks!
The company's scientifically tested products could capture a massive market with U.S. marijuana sales expected to top $30 billion in four years according to the 2020 "Marijuana Business Factbook."
Big pharma giants could be on acquisition sprees to get footing into the cannabis market and the company is focused on getting an FDA approved medicine that focuses on nausea and other ailments. As evidence of medical cannabis continues to mount, so does the industry of the global pharma industry. Big pharma has been watching from the sidelines but now that the industry is getting bigger than ever and the U.S. is headed towards federal legislation, takeover interest is intensifying!
The company is driving toward a greener future with hemp biofuels and could set to profit immensely as the world embraces the next generation of biofuels! Hemp biofuels could help lead the nation’s economy from a petroleum-based economy to a hemp-based economy.
Recent Developments
The Now Corporation Enters Into A Joint Venture With Hollywood Diagnostics Center For Human Imaging Diagnostics
NWPN is pleased to announce that, pursuant to the press release dated August 24th, it has signed a joint venture with Hollywood Diagnostics Center to perform neurological studies using state-of-the-art imaging technology to measure brain activity by detecting changes associated with blood flow when CBD compounds are introduced to the human body. The goal of the imaging data analysis is to detect correlations between brain activation in subjects when either non-tasked or tasked activities are performed during the scan with CBD compounds present. It also aims to discover correlations with cognitive states after CBD compounds are introduced to the subject. The data derived from the studies will be published to the public via the National Institute of Health (NIH) database or any other public platforms within the scientific research community.
Hollywood Diagnostics Center is a leader in the medical diagnostics field while performing over 30,000 diagnostic procedures annually. The center continues to be at the forefront of medical technology by progressively updating its equipment and procedures to reflect the latest advances in medicine. HDC has provided the healthcare community with outstanding, technologically advanced medical services to address the changing needs of patients.
The parties desire to establish between them a joint venture in order to collaborate in:
Independent industry reviews and studies (United States and internationally)
Analysis and research that measures brain activity by detecting changes associated with blood flow using cannabinoids to determine changes in brain function.
Perform blood draw findings that go along with imaging analyses.
Publishing of White Papers to National Institute of Health, and other Scientific Publishing Platforms.
Market Outlook
CBD Market Could Reach $20 Billion By 2024, Says New Study
Affecting industries as diverse as cosmetics, food and beverage and pharmaceuticals, the exploding CBD (cannabidiol) market has generated considerable headlines, providing fodder to umpteenth analysis and forecasts. The latest one, by leading cannabis researchers BDS Analytics and Arcview Market Research, projects that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024. Interestingly, this figure is a slight increase from than the recent forecast made by New York-based investment bank Cowen & Co, which estimated that the market could pull in $15 billion by 2025.
The new forecast takes into account products sold through licensed dispensaries, pharmaceuticals and in general market retail, which includes cafes, smoke shops, grocery stores and pharmacies. However, BDS Analytics predicts that the majority of CBD product sales will soon occur in general retail stores instead of cannabis dispensaries. When you consider how cannabis has become increasingly integrated into mainstream society, as represented by the number of states that have legalized recreational or medical markets (33 and D.C for recreational use and 10 states plus D.C. for adult use), the BDS prognostication makes perfect sense.
But sales will continue from other distribution channels. In fact, BDS Analytics is predicting an compound annual growth rate of 49 percent by 2024 across all distribution channels. Also, they expect that the CBD market, combined with THC products, will create a total market of $45 billion for cannabinoids by 2024.
Other findings from the new study include:
CBD product sales in dispensaries since 2014 have grown at an even faster rate than overall sales in dispensaries;
66 percent of hemp-derived CBD consumers in the U.S. agree with full federal legalization of cannabis, with 90 percent believing that marijuana has medical benefits; and
CBD consumers are an average age of 40, have higher education, and are more likely than non-consumers to be employed full time.
The U.S. market is positioned to grow under the 2018 Farm Bill, with an estimated $2.6 billion projected in sales by 2022, with $1.3 billion in sales estimated for hemp-derived CBD products by 2022!
According to the National Retail Federation, the CBD industry grew in customer demand by a whopping 700 percent in 2019.
CBD sales are also expected to reach $4 billion dollars by 2023 says the Nutrition Business Journal.
The public awareness of CBD and its many natural benefits is exploding and CBD products are flooding the market. As CBD becomes legal and more available throughout the US, increased government regulation is inevitable!
NWPN is well positioned to capitalize on the emerging opportunities resulting from the need for more research studies, product testing, hemp cultivation and production, product development, and education!
Technical Analysis
As we mentioned above, the float on NWPN is razor thin.
We did the quick math, and there is only around $662,088K worth of shares available to the public for trading.
The last time we brought this low-float alert to you attention shares ran up over +110% in just one session!
Based on our own technical analysis, we see the potential for another big move from here.
Bullish Indicators
Potential reversal trade opportunity as the stock bounced off horizontal support in confluence with the 200MA.
Bullish divergence on the RSI and MACD.
Sell exhaustion as the price stabilized on Tuesday.
First major target to the 200MA @ $0.010505.
As you know, these low-float alerts are extremely volatile, and are no strangers to triple-digit same-day moves!
The Bottom Line
We are anticipating another big move from NWPN.
From a purely technical standpoint, NWPN seems like a no brainer at the moment
Those on the hunt for big gains should add NWPN to the top of their watchlist immediately.By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)
Best regards,
Alert Price: $0.0073
Float: 90.697M
Technical Analysis
Company Website | Recent News
We are once again swinging for the fences with a proven winner that appears to be on the verge of another breakout!
Please turn your immediate attention to The Now Corporation (NWPN).
The last time we brought this low-float alert to you attention shares ran up over +110% in just one session!
Once again, NWPN’s chart is showing off several breakout signals, and it deserves to be on the top of your watchlist.
With CBD Prohibition Looking on its Last Legs, NWPN May be the Hottest Under the Radar CBD Stock Set to Skyrocket!
In the midst of growing worldwide interest in medicinal cannabis, The Now Company (NWPN) is lighting up on Wall Street with enormous profit potential ahead!
Cannabis is expected to heavily disrupt the pharmaceutical industry as patients all over the world continue to report on the medicinal benefits of the all-natural plant.
This may be the perfect time to start paying heavy attention to the sector and to NWPN, a bio-pharmaceutical research company that is focused on improving the health and wellness of patients worldwide and is building a dynamic, innovative and forward-looking research, development, education, and testing company serving the fast growing cannabis industry across the US and Canada.
About the Now Corporation
The Now Corporation is a bio-pharmaceutical research company focused on the research, education and production of Scientific-Grade Cannabidiol (CBD) from hemp and Tetrahydrocannabinol (THC) to be used for medicinal purpose, while focusing on pursuing business opportunities in the growing medical and recreational marijuana sector.
Through its acquired assets, the company is seeking to invest in its businesses associated with the growing, marketing, research and development, training, distribution and retail sale of scientific-grade medicinal cannabis, both in the United States and Canada.
This includes, but is not limited to, food, paper, and textiles derived from Hemp.
The company additionally provides Credible Scientific Research Data to the heavily regulated medical and recreational marijuana industries - currently one of the fastest growing industries in North America.
NWPN is unlocking and advancing medicine for human life around the world, at every stage of life!
The Short Term Goal
The company has created agreements with top research scientists from major Universities and have utilized their existing labs to perform expensive research using cannabinoid compounds which are in cannabis plants.
From the research, the company will be able to publish research white papers that will contain credible data from these research laboratories.
As a result, the information that NWPN publishes will start to establish increased credibility in the industry, and will allow the company's products to be prescribed by physicians since they will be able to access the information in their databases.
These studies will answer many questions and stop false data and rumors about CBD/THC derived from cannabis, and the effects on the human body.
The Long Term Goal
The company desires to have an FDA approved medicine that focuses on nausea and other ailments. Due to the FDA approval, it will be available for pharmacies to dispense, and will be on the approved list for insurance companies to pay for.
Ultimately, the company will pursue patenting the compound on a molecular level, similar to Pfizers patent on the drug, Vi-agra.
Nausea and vomiting are not diseases, but they are symptoms of many conditions such as: Motion sickness or seasickness. Early stages of pregnancy (nausea occurs in approximately 50%-90% of all pregnancies; vomiting in 25%-55%).
This makes the market for an anti-nausea medicine significant.
What Makes the Company Stand Out
NWPN will have a scientifically tested product. The existing products that are available on the markets may not be safe.
For example, what is the safe dosing for CBDs in the human body? What is the effectiveness rate when humans consume CBD, and how much can a human take before it becomes toxic to the body?
The Federal government, along with State governments must find out this answer before deeming it safe. The company's research does not start at the plant, they will also research air, soil, and water, from a seed genetic level up to a mature plant.
One reason to closely follow NWPN is because of big pharma...
On November 19, 2019, The FDA warned 15 companies for illegally selling various
products containing cannabidiol as the agency details safety concerns.
Violations included marketing unapproved new human and animal drugs, selling CBD products as dietary supplements, and adding CBD to human and animal foods.
These are concerning issues that take place in the marijuana industry and through the company's research, NWPN will address such safety concerns by performing rigorous testing of CBD compounds.
By publishing a scientific white paper based on the study, it will additionally allow the FDA to review the information and have credible data to make concrete rulings.
While the industry is big, safety concerns are still prevalent creating a demand for the type of research NWPN is involved with.
Big pharma is definitely recognizing the very lucrative opportunity when it comes to medicinal marijuana.
Cannabis is inexpensive to produce, and with the right policies, there could be widespread access to those in need, which disrupts the traditional marketplace.
A recent report found that Big Pharma stands to lose as much as $4 billion per year if medical marijuana became legal in all 50 states. The information is based off a study from 2016 by the University of Georgia, which found that states with legalized medicinal cannabis had less Medicare prescriptions than those where it's still illegal.
The study found that already pharmaceutical companies are losing $166 million annually on drugs where marijuana is now offered as an alternative.
Big pharma will have no choice but to jump onto the cannabis bandwagon if they want to continue capitalizing on patients!
Pharmaceutical giants are already preparing for the cannabis revolution and are building connections. Plus with the rise in opioid lawsuits, it may lead to many drug companies looking to cannabinoids in the search for less-addictive pain relievers.
This will only further fuel the momentum of the cannabis revolution and these pharma giants could be going on shopping sprees to scoop up smaller players.
When investors look back on the cannabis industry a decade from now, they're liable to find one of the fastest growth trends on the planet and NWPN could emerge as one of the biggest winners and acquisition targets!
A Big Vote Is On Its Way
Members of the US House of Representatives are expected to vote later this month on The Marijuana Opportunity, Reinvestment, and Expungement Act... otherwise known as The MORE Act.
This is HUGE as it is the very first time that the U.S. House will vote on federal marijuana legalization!
"It's about time," Rep. Jerry Nadler told USA TODAY, calling it a "historic vote" marking the beginning of the end of the federal government's "40-year, very misguided crusade" against marijuana.
Pot stocks like NWPN could be gearing up for a big rally as the U.S. finally pushes forward with federal marijuana legislation!
The Top 5 Reasons to Have The Now Company (OTC: NWPN) on Your Radar Right Now:
The company's CEO Ken Williams has spent five years leading public companies in the Legal Marijuana Industry, three decades of Advanced Technology Engineering, and as an executive for multi-million-dollar brands!
The U.S. is getting closer to federalizing marijuana on a federal level. The Federal government can't stick its head in the sand much longer and ignore the immense profit opportunity of the industry and the demands of the people. This could create an enormous rally for pot related stocks!
The company's scientifically tested products could capture a massive market with U.S. marijuana sales expected to top $30 billion in four years according to the 2020 "Marijuana Business Factbook."
Big pharma giants could be on acquisition sprees to get footing into the cannabis market and the company is focused on getting an FDA approved medicine that focuses on nausea and other ailments. As evidence of medical cannabis continues to mount, so does the industry of the global pharma industry. Big pharma has been watching from the sidelines but now that the industry is getting bigger than ever and the U.S. is headed towards federal legislation, takeover interest is intensifying!
The company is driving toward a greener future with hemp biofuels and could set to profit immensely as the world embraces the next generation of biofuels! Hemp biofuels could help lead the nation’s economy from a petroleum-based economy to a hemp-based economy.
Recent Developments
The Now Corporation Enters Into A Joint Venture With Hollywood Diagnostics Center For Human Imaging Diagnostics
NWPN is pleased to announce that, pursuant to the press release dated August 24th, it has signed a joint venture with Hollywood Diagnostics Center to perform neurological studies using state-of-the-art imaging technology to measure brain activity by detecting changes associated with blood flow when CBD compounds are introduced to the human body. The goal of the imaging data analysis is to detect correlations between brain activation in subjects when either non-tasked or tasked activities are performed during the scan with CBD compounds present. It also aims to discover correlations with cognitive states after CBD compounds are introduced to the subject. The data derived from the studies will be published to the public via the National Institute of Health (NIH) database or any other public platforms within the scientific research community.
Hollywood Diagnostics Center is a leader in the medical diagnostics field while performing over 30,000 diagnostic procedures annually. The center continues to be at the forefront of medical technology by progressively updating its equipment and procedures to reflect the latest advances in medicine. HDC has provided the healthcare community with outstanding, technologically advanced medical services to address the changing needs of patients.
The parties desire to establish between them a joint venture in order to collaborate in:
Independent industry reviews and studies (United States and internationally)
Analysis and research that measures brain activity by detecting changes associated with blood flow using cannabinoids to determine changes in brain function.
Perform blood draw findings that go along with imaging analyses.
Publishing of White Papers to National Institute of Health, and other Scientific Publishing Platforms.
Market Outlook
CBD Market Could Reach $20 Billion By 2024, Says New Study
Affecting industries as diverse as cosmetics, food and beverage and pharmaceuticals, the exploding CBD (cannabidiol) market has generated considerable headlines, providing fodder to umpteenth analysis and forecasts. The latest one, by leading cannabis researchers BDS Analytics and Arcview Market Research, projects that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024. Interestingly, this figure is a slight increase from than the recent forecast made by New York-based investment bank Cowen & Co, which estimated that the market could pull in $15 billion by 2025.
The new forecast takes into account products sold through licensed dispensaries, pharmaceuticals and in general market retail, which includes cafes, smoke shops, grocery stores and pharmacies. However, BDS Analytics predicts that the majority of CBD product sales will soon occur in general retail stores instead of cannabis dispensaries. When you consider how cannabis has become increasingly integrated into mainstream society, as represented by the number of states that have legalized recreational or medical markets (33 and D.C for recreational use and 10 states plus D.C. for adult use), the BDS prognostication makes perfect sense.
But sales will continue from other distribution channels. In fact, BDS Analytics is predicting an compound annual growth rate of 49 percent by 2024 across all distribution channels. Also, they expect that the CBD market, combined with THC products, will create a total market of $45 billion for cannabinoids by 2024.
Other findings from the new study include:
CBD product sales in dispensaries since 2014 have grown at an even faster rate than overall sales in dispensaries;
66 percent of hemp-derived CBD consumers in the U.S. agree with full federal legalization of cannabis, with 90 percent believing that marijuana has medical benefits; and
CBD consumers are an average age of 40, have higher education, and are more likely than non-consumers to be employed full time.
The U.S. market is positioned to grow under the 2018 Farm Bill, with an estimated $2.6 billion projected in sales by 2022, with $1.3 billion in sales estimated for hemp-derived CBD products by 2022!
According to the National Retail Federation, the CBD industry grew in customer demand by a whopping 700 percent in 2019.
CBD sales are also expected to reach $4 billion dollars by 2023 says the Nutrition Business Journal.
The public awareness of CBD and its many natural benefits is exploding and CBD products are flooding the market. As CBD becomes legal and more available throughout the US, increased government regulation is inevitable!
NWPN is well positioned to capitalize on the emerging opportunities resulting from the need for more research studies, product testing, hemp cultivation and production, product development, and education!
Technical Analysis
As we mentioned above, the float on NWPN is razor thin.
We did the quick math, and there is only around $662,088K worth of shares available to the public for trading.
The last time we brought this low-float alert to you attention shares ran up over +110% in just one session!
Based on our own technical analysis, we see the potential for another big move from here.
Bullish Indicators
Potential reversal trade opportunity as the stock bounced off horizontal support in confluence with the 200MA.
Bullish divergence on the RSI and MACD.
Sell exhaustion as the price stabilized on Tuesday.
First major target to the 200MA @ $0.010505.
As you know, these low-float alerts are extremely volatile, and are no strangers to triple-digit same-day moves!
The Bottom Line
We are anticipating another big move from NWPN.
From a purely technical standpoint, NWPN seems like a no brainer at the moment
Those on the hunt for big gains should add NWPN to the top of their watchlist immediately.By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)
Best regards,